MarketMoodz
QURE — uniQure N.V.
Is QURE overbought or oversold? Here is the current MarketMoodz read.
uniQure N.V. (QURE) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Biotechnology) last closed at $41.81. The rating moved from Neutral to Oversold on June 30, 2026 and has changed 23 times in the last 90 days.
- Public ratingOversold (as of July 5, 2026)
- Last close$41.81
- Rating changesRating changed 23 times in the last 90 days
- Last changeMoved from Neutral to Oversold on June 30, 2026
- SectorHealthcare
- IndustryBiotechnology
Latest MarketMoodz coverage
- FDA Accelerated Pathway Spurs uniQure Surge, Shifts Biotech Bets2026-06-18
- FDA Signals AMT-130 Data Could Support Accelerated Approval2026-06-17
- Moderna, Capricor Lead Biotech Movers on FDA Shakeups and HOPE-3 Data2026-03-09
- FDA Defends Placebo Trial for uniQure Huntington's Gene Therapy2026-03-05
- UniQure stock slides 40% after FDA signals AMT-130 data can't support filing2026-03-02
See today's live rating, score and targets
Members see the live hourly rating for QURE — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.